Form 4: Immix Biopharma Director Jason Hsu Acquires Additional Shares

Director Jason Hsu reports purchasing additional shares of Immix Biopharma, Inc. in two transactions.

Summary

• Jason Hsu, a director of Immix Biopharma, Inc., acquired additional shares of common stock.
• On December 20, 2024, Hsu purchased 7,700 shares at a weighted average price of $2.166 per share.
• On December 23, 2024, Hsu purchased 40,000 shares at a weighted average price of $2.192 per share.
• Following these transactions, Hsu directly owns 893,000 shares of Immix Biopharma common stock.
• Hsu also indirectly owns 3,915,913 shares through VERITAS LIBERABIT VOS, LLC and 50,000 shares through Signature Collection Properties, LLC.
• Hsu disclaims beneficial ownership of shares held by VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is neutral. Insider buying can be seen as a positive signal, but without additional context, it's difficult to gauge the overall impact.

Positives

• Director's purchase may signal confidence in the company's future prospects.

Industry Context

Tracking insider transactions provides insights into management's perspective on the company's valuation and future performance relative to the biotechnology industry.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive sign.

Key Dates